EDESA BIOTECH, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
EDESA BIOTECH, INC. (EDSA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $200.00 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-12-12
- EDESA BIOTECH, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $200.00K, a 36.05% increase from fiscal 2024.
- EDESA BIOTECH, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $147.00K, a 56.64% decline from fiscal 2023.
- EDESA BIOTECH, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $339.00K, a 47.85% decline from fiscal 2022.
- EDESA BIOTECH, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $650.00K, a 23.26% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|---|
| 2025-09-30 | $200.00K 10-K · filed 2025-12-12 | |
| 2024-09-30 | $147.00K 10-K · filed 2025-12-12 | |
| 2023-09-30 | $339.00K 10-K · filed 2024-12-13 | |
| 2022-09-30 | $650.00K 10-K · filed 2023-12-15 | |
| 2021-09-30 | $847.00K 10-K · filed 2022-12-16 | |
| 2020-09-30 | $159.00K 10-K · filed 2021-12-28 | |
| 2019-09-30 | $11.00K 10-K · filed 2020-12-07 | |
| 2018-12-31 | $41.00K 10-KT · filed 2019-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |